Compare Costco Wholesale Corporation (COST) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Crispr Therapeutics AG — how do they compare? Costco Wholesale Corporation trades at $945.42 (market cap $420.05B), while Crispr Therapeutics AG trades at $53.6 (market cap $4.88B). The key difference: Costco Wholesale Corporation is far larger — about 86.1× Crispr Therapeutics AG's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and Crispr Therapeutics AG for 77 Days on average.
| COST | CRSP | |
|---|---|---|
Market Cap | $420.05B | $4.88B |
Volume | 2,087,565 | 2,861,747 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $74.92 |
52-Week Low | $849.63 | $44.34 |
Typical Hold Time | 132 Days | 77 Days |
Enterprise Value | $407.33B | $3.30B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $944.20, up 0.21% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year (Costco Wholesale Corporation, April 8, 2026) and has shown consistent revenue and net income growth, with fiscal 2025 revenue at $275.24B and net income at $8.10B. Analyst consensus is strongly bullish with a $1,100 price target, though valuation ratios like a P/E of 45.66 are elevated.
The outlook remains positive due to robust membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Upside is supported by strong institutional buying and earnings beats, though any market pullback could pressure the stock given its premium multiples.
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
